Bronchial Thermoplasty (BT) Is For Adult Patients With Severe Asthma For Whom Medication, Alone, Isn't Enough
Some patients still experience exacerbations and significantly limit their quality of life (assessed by AIS-6 or AQLQ), despite their recommended medication regimen.
These patients can benefit from Bronchial Thermoplasty to reduce their exacerbations. Fewer exacerbations means less need for the associated oral steroid treatment—and its side effects.
BT is for:
Patients on maximum tolerated doses of combined ICS and LABA such as Advair™, Dulera™ and Symbicort™, and patients who experience one or more of the following:
- Patients who take oral steroids for acute exacerbations more than twice a year
- Patients who are Anti-IgE therapy candidates or non-responders
- Patients who take oral steroids as daily maintenance medication
Societies Support Bronchial Thermoplasty As A Therapy For Patients With Severe Asthma
BT Is Included In Asthma Guidelines And Strategy Statements
Global Asthma Experts Explain Who Benefits from BT
— Robert Niven, MD
Global Asthma Experts Explain How BT Improves Quality of Life
— Carla Lamb, MD
BT Is Not For Patients Who:
- Are under 18 years old
- Have a pacemaker, internal defibrillator, or other implantable electronic device
- Have a known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, and benzodiazepines
- Have been treated previously with BT
Have your patients take this peer-reviewed, clinically-validated Asthma Impact Survey to assess the impact of asthma on their quality of life
Patients Who Chose BT To Better Manage Their Severe Asthma
Watch Richard Jefferson's Story
- Adapted from the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/.
- American College of Asthma, Allergy and Immunology (ACAAI). Statement On Bronchial Thermoplasty. May 2015.
- INTERASMA (Global Asthma Association). Bronchial Thermoplasty: An Additional Option for Managing Patients with Severe Asthma. October 2014
- CHEST American College of Chest Physicians. Position Statement for Coverage and Payment for Bronchial Thermoplasty. May 12, 2014
- Allergy & Asthma Network (AAN). Bronchial Thermoplasty. June 2015
- Asthma Allergy Foundation of America (AAFA). Patient Advocacy Support for Full Medical Coverage for Bronchial Thermoplasty (BT) to Treat Severe Asthma. 2009
- From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. May 19, 2015
- GEMA4.0. Guía española para el manejo del asma © 2015, Comité Ejecutivo de la GEMA. Todos los derechos reservados ISBN: 978-84-7989-840-3. Depósito legal: M-13523-2015.
- Associazione Italiana Pneumologi Ospedalieri (AIPO). Rassegna di Patologia dell'Apparato Respiratorio - fascicolo 1/2015.
- British Thoracic Society (BTS). British guideline on the management of asthma. October 2014.
- Kian Fan Chung et al: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373 | DOI: 10.1183/09031936.00202013
- Wechsler ME and Cox GP. Letter to Editor. Eur Respir J 2014; 44: 267 | DOI: 10.1183/09031936.00043514
- Kian Fan Chung, Sally E. Wenzel and Jan L. Brozek for the ERS/ATS Task Force on Definition, Evaluation and Treatment of Severe Asthma. Response to Letter to Editor. Eur Respir J 2014; 44: 267–268 | DOI: 10.1183/09031936.00064614
Brief Statement of Relevant Indications for Use, Contraindications, Warnings, and Adverse Events: The Alair™ Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists. The Alair System is not for use in patients with an active implantable electronic device or known sensitivity to medications used in bronchoscopy. Previously treated airways of the lung should not be retreated with the Alair System. Patients should be stable and suitable to undergo bronchoscopy. The most common side effect of BT is an expected transient increase in the frequency and worsening of respiratory-related symptoms.